AUG 31·SEC EDGARLow
LEDERMAN SETH purchased $28K of TNXP (indirect holdings)
LEDERMAN SETH (Chief Executive Officer) purchased 2,000 indirectly-held shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $13.79 on 2026-08-27.
StockNASDAQ · US · USDHealthcare · Biotechnology
$TNXP
Tonix Pharmaceuticals Holding Corp.
alphai earnings readSecond Quarter 2026 · AUG 10TONMYA net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter, while Tonix reported approximately $176.2 million in cash and cash equivalents as of June 30, 2026.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $TNXPvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $TNXP in the last 7 days.
Insider · 30dAll trades →
- Buys
- $40K 2 txs
- Sells
- — 0 txs
LEDERMAN SETH1× · $28K
10b5-1 share of filings0%
Top stories · $TNXPMore →
AUG 24·infectioncontroltoday.com
Next-Generation Mpox Vaccine Shows Promise for Durable Protection and Future Outbreak Preparedness
Tonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin
AUG 24·SEC EDGAR
BAGGER RICHARD H purchased $13K of TNXP
BAGGER RICHARD H purchased 1,000 shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $12.60 on 2026-08-20.
TNXP sentiment & insider activity
Recent TNXP coverage spans earnings, insider activity and technology.
In the last 30 days, TNXP insiders filed 2 SEC Form 4 transactions — 2 purchases ($40K) and no sales. The most active reporter was LEDERMAN SETH, Chief Executive Officer, with 1 filing.
What's driving TNXP
Insider buying may signal confidence, but the purchase size is modest.
First public disclosure of TNX-801 preclinical efficacy and durability.
Small insider purchase signals modest confidence but limited market impact.
The filing signals a leadership reshuffle in medical oversight, which can affect clinical execution and near-term investor sentiment, but it provides no clinical or financial metrics.
The call provides fresh, decision-relevant operating metrics for TONMYA commercialization plus updated development and cash runway details.
alphai scores every news story that mentions TNXP with an AI model for sentiment and relevance, and aggregates insider trades from Tonix Pharmaceuticals Holding Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TNXP
Score
LEDERMAN SETH purchased $28K of TNXP (indirect holdings)
LEDERMAN SETH (Chief Executive Officer) purchased 2,000 indirectly-held shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $13.79 on 2026-08-27.
1 min read
Next-Generation Mpox Vaccine Shows Promise for Durable Protection and Future Outbreak Preparedness
Tonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin
3 min readBAGGER RICHARD H purchased $13K of TNXP
BAGGER RICHARD H purchased 1,000 shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $12.60 on 2026-08-20.
1 min readTonix Pharmaceuticals Holding Corp. (TNXP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Interim Chief Medical Officer On August 18, 2026, the Board of Directors of Tonix Pharmaceuticals Holding Corp. (the “Compa
3 min read
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.
6 min readTonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns
Tonix Pharmaceuticals Holding reported Q2 2026 revenue of about $13.544M, up from $1.998M a year earlier, largely driven by TONMYA sales (about $11M). The company posted a net loss of about $40.552M, and basic EPS loss narrowed to $2.44. The stock fell about 2% on the day.
6 min readTonix Pharmaceuticals Q2 Earnings Call Highlights
Tonix Pharmaceuticals (NASDAQ:TNXP) reported Q2 call updates on Tonmya market access. Coverage was about 136M lives (43%) and is expected to rise to ~145M (46%) from a Jan. 1, 2027 GPO deal. Tonix added 50 sales reps, targeting ~150 by September. Pipeline: HORIZON Phase II TNX-102 SL in MDD (enroll ~360) and Lyme prevention Phase II (enroll ~3,300). Cash: ~$176.2M.
4 min read
Tonix Pharmaceuticals Reports Strong Q2 2026 Revenue, TONMYA Sales Surge
Tonix Pharmaceuticals (NASDAQ: TNXP) reported Q2 2026 net product revenue of about $13.5M versus $2M a year earlier, driven by TONMYA net sales of about $11M. TONMYA prescriptions totaled 12,592, up 100% sequentially. TONMYA coverage is ~136M lives, rising to ~145M from Jan. 1, 2027. Cash was ~$176.2M.
4 min read
TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027
Tonix Pharmaceuticals Holding Corp. (TNXP) reported Q2 2026 revenue growth attributed to Tonmya’s launch, broader market access, and refill dynamics. The company said pipeline programs advanced, including pivotal studies for MDD and Lyme disease prevention. Tonix also stated its cash runway extends into early Q2 2027, per its Q2 2026 audio transcript.
1 min readTonix Pharmaceuticals Holding Corp. (TNXP): Results of Operations and Financial Condition
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, no
7 min read